Skip to content

Delcath Systems DCTH Additional Paid-In Capital

Additional Paid-In Capital at other companies

Altimmune logo
AltimmuneALT
$961.24M+32.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$1.41B+1.2%
Wave Life Sciences logo
Wave Life SciencesWVE
$237.43M+47.1%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$1.7B+90.5%
Immunome logo
ImmunomeIMNM
$1.37B+58.5%
LQD
Liquidia CorporationLQDA
$681.94M+5.7%

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's additional paid-in capital?
Delcath Systems (DCTH) reported additional paid-in capital of $641.71M in Q1 2026.
How has Delcath Systems's additional paid-in capital changed year-over-year?
Delcath Systems's additional paid-in capital increased by 5.2% year-over-year, from $609.99M to $641.71M.
What is the long-term trend for Delcath Systems's additional paid-in capital?
Over 5 years (2020 to 2025), Delcath Systems's additional paid-in capital has grown at a 8.9% compound annual growth rate (CAGR), from $417.45M to $639.15M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.